Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

We previously reported durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) patients treated with CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T-cell immunotherapy after ibrutinib failure. Because preclinical studies showed that ibrutinib could improv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Gauthier, Jordan, Hirayama, Alexandre V., Purushe, Janaki, Hay, Kevin A., Lymp, James, Li, Daniel H., Yeung, Cecilia C. S., Sheih, Alyssa, Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Phi, Tinh-Doan, Steinmetz, Rachel N., Shadman, Mazyar, Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7205814/
https://ncbi.nlm.nih.gov/pubmed/32076701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019002936
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados